Available to sourceHuman Prescription DrugOncology & Specialty

PEMAZYRE (pemigatinib)

4.5 mg/1 · Tablet

By Incyte Corporation

NDC: 50881-026
Route: Oral
Therapeutic class: Kinase Inhibitor , Kinase Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]
Marketing category: NDA

Additional information

Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.

Request this medication

Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.

Related in Oncology & Specialty

See all →

PEMAZYRE (pemigatinib)

Additional information

Request this medication

Related in Oncology & Specialty

Verzenio (abemaciclib)

Verzenio (abemaciclib)

Verzenio (abemaciclib)

Verzenio (abemaciclib)